Dr. Reddy’s Laboratories announced its audited financial results for the quarter and financial year ended March 31, 2026. The company reported annual revenue of ₹33,593 crore, reflecting a 3% year-on-year growth. Despite specific headwinds, the company achieved double-digit growth in its base business, supported by strategic productivity efforts and an expanded product portfolio in key global markets.
Financial Performance Overview
For the fourth quarter of the financial year 2026, Dr. Reddy’s reported revenues of ₹7,516 crore. Before the impact of specific items such as the ₹453 crore shelf stock adjustment for lenalidomide, the company maintained a robust 19.5% EBITDA margin. For the full fiscal year, the company reached ₹33,593 crore in revenue, with an EBITDA of ₹7,659 crore and a net cash surplus of ₹3,271 crore, underscoring strong operational discipline.
Strategic Business Highlights
The company achieved several significant milestones during the quarter. Key accomplishments include the first-to-market approval for a generic semaglutide injection in Canada and the launch of the brand ‘Obeda®’ in India. Additionally, the company secured approval for generic semaglutide tablets in India and expanded its presence into the Hormone Replacement Therapy segment through the acquisition of the Progynova® and Cyclo-Progynova® brands.
Geographic and Segment Growth
Global Generics remains the primary driver, accounting for 89% of annual revenue. Emerging Markets performed particularly well, with a 23% year-on-year growth driven by new product launches and higher volume uptake. While North America experienced product-specific headwinds, the company’s commitment to R&D continues with 75 pending ANDAs and 2 NDAs currently in the pipeline. Furthermore, the company’s CDMO business under Aurigene Pharmaceutical Services Limited continues to demonstrate strong market traction.
Commitment to Sustainability
Dr. Reddy’s continues to prioritize governance and environmental impact. The company received a Gold Medal from EcoVadis for FY26, achieving its highest-ever sustainability score of 80 and placing it among the top 5% of companies assessed globally. It was also recognized as one of India’s Top 5 Most Sustainable Companies by BusinessWorld for 2024-25, alongside a ‘Leadership category’ rating in the 2025 Indian Corporate Governance Scorecard.
Source: BSE
